For many hematological malignancies (HMs) survival among older patients is compromised. We want to test the most up-to-date age-group-specific survival differences in five hematological malignancies, Hodgkin lymphoma (HL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) in Sweden (SE) and compared these to Denmark, Finland and Norway. For analysis we apply a recently published metric for comparing and visualizing age-group-specific relative survival differences using data from the NORDCAN database between 1972 and 2021. Periodic changes in age-related deviation in SE survival showed increasing differences for AML and MM while for the other HMs the differences declined in the course of time. Country-specific differences were observed, for Finnish male CLL and female MPD deviations were larger than those for the other countries, both of which were explained by the deviant survival of the oldest patients. Age-related deviations in 5-year survival increased for AML and MM for which survival improvements have been achieved through intense treatment regimens but these are not offered to old patients because of risk of complications. Paradoxically, improving overall survival in AML and MM has contributed to the widening of the age gaps. For the remaining HMs, age-related deviations declined with time as even old patients benefitted from the survival improvements; most notably female MPD and CLL patients had hardly any age gaps. Age disparities are an issue in hematological malignancies, and an intense search for novel treatments also includes old patients with an example of success as a novel drug venetoclax.

Biomedical Center Faculty of Medicine and Biomedical Center in Pilsen Charles University Prague Pilsen 30605 Czech Republic

Division of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 580 Heidelberg 69120 Germany

See more in PubMed

Hemminki K, Hemminki J, Försti A, Sud A (2022) Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J 12(11):150 PubMed PMC

Hemminki K, Hemminki J, Försti A, Sud A (2023) Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia 37(4):854–863 PubMed PMC

Pulte D, Jansen L, Brenner H (2020) Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J 10(5):56 PubMed PMC

DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643–8653 PubMed

Crisci S, Amitrano F, Saggese M, Muto T, Sarno S, Mele S et al (2019) Overview of current targeted anti-cancer drugs for therapy in onco-hematology. Medicina (Kaunas) 55(8):414 PubMed PMC

Olejarz W, Basak G (2023) Emerging therapeutic targets and drug resistance mechanisms in immunotherapy of hematological malignancies. Cancers 15(24):5765 PubMed PMC

Tang L, Huang Z, Mei H, Hu Y (2023) Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther 8(1):306 PubMed PMC

Evens AM, Hutchings M, Diehl V (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5(9):543–556 PubMed

Pui CH, Nichols KE, Yang JJ (2019) Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 16(4):227–240 PubMed

Yang B, Yu R, Cai L, Bin G, Chen H, Zhang H et al (2019) Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis. Bone Marrow Transplant 54(1):99–122 PubMed

Khan M, Maker AV, Jain S (2021) The Evolution of Cancer Immunotherapy. Vaccines (Basel). 9(6):614 PubMed PMC

De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G et al (2015) Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study. Eur J Cancer 51(15):2254–2268 PubMed

Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B et al (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 15(9):931–942 PubMed

Pulte D, Jansen L, Castro FA, Brenner H (2016) Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer 122(13):2031–2040 PubMed

Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM (2020) Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev 42:100706 PubMed

Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E et al (2022) Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol 108(2):99–108 PubMed

Juliusson G, Hagberg O, Lazarevic VL, Ölander E, Antunovic P, Cammenga J et al (2019) Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood 134(18):1558–1561 PubMed PMC

Naur TMH, Jakobsen LH, Roug AS, El-Galaly TC, Marcher CW, Nørgaard JM et al (2021) Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001–2016: a Danish nationwide cohort study. Leuk Lymphoma 62(8):2014–2017 PubMed

da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU (2016) Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J 6(11):e499 PubMed PMC

Hemminki K, Zitricky F, Försti A, Kontro M, Gjertsen BT, Severinsen MT et al (2024) Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Blood Cancer J 14(1):44 PubMed PMC

Hemminki K, Zitricky F, Försti A, Silvennoinen R, Vangsted A, Hansson M (2024) Large differencies in age-specific survival in multiple myeloma in the nordic countries. Blood Cancer J 14(1):43 PubMed PMC

Cordoba R, Eyre TA, Klepin HD, Wildes TM, Goede V (2021) A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematol 8(11):e840–e852 PubMed

Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A et al (2010) NORDCAN–a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 49(5):725–736 PubMed

Pukkala E, Engholm G, Hojsgaard Schmidt LK, Storm H, Khan S, Lambe M et al (2018) Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol 57:440–455 PubMed

Larønningen SAG, Bray F, Engholm G, Ervik M, Guðmundsdóttir EM, Gulbrandsen J, Hansen HL, Hansen HM, Johannesen TB, Kristensen S, Kristiansen MF, Lam F, Laversanne M, Miettinen J, Mørch LS, Ólafsdóttir E, Pejicic S, Petterson D, Steig BÁ, Skog A, Tian H, Aagnes B, Storm HH (2023) NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 9.3 (02.10.2023)

Pohar Perme M, Estève J, Rachet B (2016) Analysing population-based cancer survival - settling the controversies. BMC Cancer 16(1):933 PubMed PMC

Zitricky F, Hemminki K (2024) A metric for comparison and visualization of age disparities in cancer survival. Cancer Epidemiol 91:102586 PubMed

Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust T et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20(11):1493–1505 PubMed PMC

Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Allemani C et al (2009) The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer 45:1006–1016 PubMed

Withrow DR, Nicholson BD, Morris EJA, Wong ML, Pilleron S (2023) Age-related differences in cancer relative survival in the United States: a SEER-18 analysis. Int J Cancer 152(11):2283–2291 PubMed

Schuurman MS, Lemmens V, Portielje JEA, van der Aa MA, Visser O, Dinmohamed AG (2024) The cancer burden in the oldest-old: increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019. Int J Cancer 154(2):261–272 PubMed

De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15(1):23–34 PubMed

Pilleron S, Charvat H, Araghi M, Arnold M, Fidler-Benaoudia MM, Bardot A et al (2021) Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. Int J Cancer 148(7):1575–1585 PubMed

Hemminki K, Försti A, Hemminki A (2021) Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterol 8(1):e000644 PubMed PMC

Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O (2021) Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLoS ONE 16(6):e0253236 PubMed PMC

Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O (2022) Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS ONE 17(1):e0261124 PubMed PMC

Dores GM, Curtis RE, Dalal NH, Linet MS, Morton LM (2020) Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin Lymphoma, 2000–2016. J Clin Oncol 38(35):4149–4162 PubMed PMC

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–1377 PubMed

Fey M, Dreyling M (2009) Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):100–101 PubMed

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D et al (2019) Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN 17(6):721–49 PubMed

Hemminki K, Försti A, Houlston R, Sud A (2021) Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer 149(12):1980–1996 PubMed PMC

Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M et al (2024) Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol 99:193–202 PubMed

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C et al (2023) First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 388(19):1739–1754 PubMed

Khan WJ, Ali M, Hashim S, Nawaz H, Hashim SN, Safi D et al (2023) Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review. J Oncol Pharm Pract 30(3):10781552231219000 PubMed

Raab MS (2024) Venetoclax in myeloma: to B, or not to B. Blood 143(1):4–5 PubMed